Oncternal Therapeutics Statistics
Total Valuation
TMCI has a market cap or net worth of $382.20 million. The enterprise value is $388.06 million.
Important Dates
The last earnings date was Thursday, August 7, 2025, after market close.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
TMCI has 63.17 million shares outstanding. The number of shares has increased by 1.25% in one year.
| Current Share Class | 63.17M |
| Shares Outstanding | 63.17M |
| Shares Change (YoY) | +1.25% |
| Shares Change (QoQ) | +0.55% |
| Owned by Insiders (%) | 25.02% |
| Owned by Institutions (%) | 52.38% |
| Float | 47.37M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 1.79 |
| Forward PS | 1.59 |
| PB Ratio | 3.96 |
| P/TBV Ratio | 5.02 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.82 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.52, with a Debt / Equity ratio of 0.72.
| Current Ratio | 3.52 |
| Quick Ratio | 2.39 |
| Debt / Equity | 0.72 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -9.10 |
Financial Efficiency
Return on equity (ROE) is -46.89% and return on invested capital (ROIC) is -17.10%.
| Return on Equity (ROE) | -46.89% |
| Return on Assets (ROA) | -13.83% |
| Return on Invested Capital (ROIC) | -17.10% |
| Return on Capital Employed (ROCE) | -29.08% |
| Revenue Per Employee | $448,115 |
| Profits Per Employee | -$103,105 |
| Employee Count | 477 |
| Asset Turnover | 0.99 |
| Inventory Turnover | 1.02 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -5.69% in the last 52 weeks. The beta is 0.68, so TMCI's price volatility has been lower than the market average.
| Beta (5Y) | 0.68 |
| 52-Week Price Change | -5.69% |
| 50-Day Moving Average | 5.81 |
| 200-Day Moving Average | 7.30 |
| Relative Strength Index (RSI) | 59.05 |
| Average Volume (20 Days) | 299,112 |
Short Selling Information
The latest short interest is 2.74 million, so 4.34% of the outstanding shares have been sold short.
| Short Interest | 2.74M |
| Short Previous Month | 2.71M |
| Short % of Shares Out | 4.34% |
| Short % of Float | 5.79% |
| Short Ratio (days to cover) | 8.91 |
Income Statement
In the last 12 months, TMCI had revenue of $213.75 million and -$49.18 million in losses. Loss per share was -$0.79.
| Revenue | 213.75M |
| Gross Profit | 171.25M |
| Operating Income | -47.84M |
| Pretax Income | -63.68M |
| Net Income | -49.18M |
| EBITDA | -39.41M |
| EBIT | -47.84M |
| Loss Per Share | -$0.79 |
Full Income StatementBalance Sheet
The company has $69.29 million in cash and $70.09 million in debt, giving a net cash position of -$805,000 or -$0.01 per share.
| Cash & Cash Equivalents | 69.29M |
| Total Debt | 70.09M |
| Net Cash | -805,000 |
| Net Cash Per Share | -$0.01 |
| Equity (Book Value) | 97.62M |
| Book Value Per Share | 1.55 |
| Working Capital | 105.70M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$14.90 million and capital expenditures -$14.25 million, giving a free cash flow of -$29.15 million.
| Operating Cash Flow | -14.90M |
| Capital Expenditures | -14.25M |
| Free Cash Flow | -29.15M |
| FCF Per Share | -$0.46 |
Full Cash Flow StatementMargins
Gross margin is 80.12%, with operating and profit margins of -22.38% and -23.01%.
| Gross Margin | 80.12% |
| Operating Margin | -22.38% |
| Pretax Margin | -23.01% |
| Profit Margin | -23.01% |
| EBITDA Margin | -18.44% |
| EBIT Margin | -22.38% |
| FCF Margin | n/a |
Dividends & Yields
TMCI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.25% |
| Shareholder Yield | -1.25% |
| Earnings Yield | -12.70% |
| FCF Yield | -7.53% |
Analyst Forecast
The average price target for TMCI is $8.60, which is 42.15% higher than the current price. The consensus rating is "Hold".
| Price Target | $8.60 |
| Price Target Difference | 42.15% |
| Analyst Consensus | Hold |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TMCI has an Altman Z-Score of 1.82 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.82 |
| Piotroski F-Score | 2 |
